ライフサイエンスコーパス: off-label use

1 nappropriate for inclusion in a study (e.g., off-label use).

2 BDQ and DLM are extended beyond 24 weeks as off-label use.

3 riod of over 50 days is indicated in case of off-label use.

4 BDQ and DLM are extended beyond 24 weeks as off-label use.

5 Overall, 977 infants (18.8%) received off-label use.

6 treatment in the concept of repurposing and off-label use.

7 ved crizotinib therapy through an individual off-label use.

8 for Food and Drug Administration-approved or off-label use.

9 , with concomitant increases in dabigatran's off-label use.

10 e and duration of treatment as well as their off-label use.

11 among atypical antipsychotic medications for off-label use.

12 ere weakly associated with the likelihood of off-label use.

13 or headache, mood disorders, and unknown or off-label uses.

14 ontin, Pfizer, Inc., New York, New York) for off-label uses.

15 larly for P-tribe, despite being considered "off-label" use.

16 for Food and Drug Administration-approved or off-label use (0.74% vs 0.67%; p = 0.336; 33 vs 31 event

17 site end point was significantly higher with off-label use (adjusted hazard ratio [HR], 2.08; 95% con

18 s end point was not different at 1 year with off-label use (adjusted HR, 1.10; 95% CI, 0.79-1.54; P =

19 essel revascularization were associated with off-label use (adjusted HR, 1.49; 95% CI, 1.13-1.98; P =

20 reactions do not occur more frequently with off-label use, adverse drug reaction risk increases with

21 On-label use amounted to 70%, and off-label use amounted to 30%.

22 ce of adverse drug reactions associated with off-label use and evaluate off-label use as a risk facto

23 Excluding off-label use and pregnancy, 438 patients (78.6%) did no

24 ng and number of surfactant administrations, off-label use, and omission of use.

25 ard use, relative early safety is lower with off-label use, and the long-term effectiveness is lower

26 However, it is an off-label use, and the potential side effects of dexmede

27 s associated with off-label use and evaluate off-label use as a risk factor for the development of ad

28 ibed promotion of the same drug for the same off-label use as was alleged by whistleblowers in the US

29 eterization laboratory-only eptifibatide (an off-label use) as procedural pharmacotherapy for patient

30 %), with hospitals in the highest tertile of off-label use associated with increased 30-day adverse c

31 re safe and efficacious in both on-label and off-label use but highlight differences between RCT and

32 rials in children, which might reduce unsafe off-label use by promoting more quickly proper labeling

33 agonists should not be offered routinely but off-label use can be considered in selected children.

34 Early off-label use data on TMVR in mitral valve-in-valve ther

35 Rate ratios were similar during the off-label use era and after pediatric labeling.

36 re not approved for use in the forehead, but off-label use for enhancement in this region is common.

37 EDTA chelation therapy has been in off-label use for the treatment of atherosclerosis.

38 The CMS would pay only for off-label uses for which there is adequate evidence in i

39 seven ADRs lacking PI changes occurred with off-label use, for which PI change is not recommended by

40 Off-label use has been promoted because of the paucity o

41 is common in the ICU; however, the safety of off-label use has not been assessed.

42 ations, their unanticipated side effects and off-label use have contributed significantly to our unde

43 in Europe for olodaterol or indacaterol for off-label use in asthma or for pediatric use.

44 rol in clinical practice and to quantify the off-label use in asthma.

45 uring treatment for hypothyroidism or during off-label use in euthyroid individuals, has not proven t

46 disclosures made in articles related to the off-label use in question, determined the frequency of a

47 th BRAF inhibitors in clinical trials and as off-label use in routine practice by presenting 3 challe

48 Novel "off-label" uses in children for interleukin-1 receptor a

49 For each off-label use indication with 3 or more requests, random

50 ence on benefits for OS or PFS for requested off-label use indications.

51 The extent of off-label use is a policy concern because the clinical b

52 tor medication in the United States, but its off-label use is associated with risks associated with t

53 Prior research indicates that off-label use is common in the ICU; however, the safety

54 Off-label use is composed of a roughly equal mix of chem

55 t in a health care system enabling access to off-label use, it was frequently intended as a first-lin

56 position) and articles (type, connection to off-label use, journal impact factor, citation count/yea

57 gle intravitreal injection of bevacizumab in off-label use (n = 33 eyes) or peripheral laser ablation

58 Off-label use occurred in 54.7% of all patients with bar

59 Caution is thus required with the off-label use of a perioperative intravenous n-3 PUFA em

60 In addition, off-label use of a third anti-VEGF agent, bevacizumab, a

61 ces (CMS) each created initiatives to reduce off-label use of antipsychotics in patients with dementi

62 MLV-related viruses, including XMRV, and the off-label use of antiretrovirals for the treatment of CF

63 It could be argued that all off-label use of any agent should be deemed illegal.

64 While investigating the off-label use of BDQ as salvage therapy, seven of 13 pat

65 d for the analysis of real-world data on the off-label use of bulevirtide in the setting of decompens

66 pares annulus measurements from 3D-TEE using off-label use of commercially available software with MD

67 eosinophilic esophagitis (EoE) is limited to off-label use of corticosteroids not optimized for esoph

68 eosinophilic esophagitis (EoE) is limited to off-label use of corticosteroids not optimized for esoph

69 yrin production, we treated the patient with off-label use of deferasirox to maintain iron deficiency

70 sting for drugs, and this policy perpetuates off-label use of devices and creates several issues in p

71 However, the off-label use of dexmedetomidine in premature infants ha

72 Recent reports suggest that off-label use of drug-eluting stents is associated with

73 Compared with on-label use, off-label use of drug-eluting stents is associated with

74 , highlighting the risks associated with the off-label use of drugs in newborn infants before safety

75 because of access to clinical trials and/or off-label use of drugs.

76 Off-label use of empagliflozin in 4 GSD-Ib patients with

77 he purpose of this study was to evaluate the off-label use of ePlex Blood Culture Identification Pane

78 D-19 are limited to supportive therapies and off-label use of FDA-approved drugs.

79 rend continued until the mid-1990s, when the off-label use of fenfluramine plus phentermine (fen-phen

80 Studies in the literature suggest that the off-label use of fibrin glue to close limbal conjunctiva

81 ed selective outcome reporting for trials of off-label use of gabapentin.

82 ugs and substantial medical need justify the off-label use of HCV PIs in select HIV/HCV-coinfected pe

83 Safety concerns arose because of common off-label use of higher doses, particularly after pediat

84 article, we review the existing data on this off-label use of LA CAB/RPV, discuss the motivations and

85 The results of small studies suggest that off-label use of low-dose oral minoxidil (LDOM) may be s

86 Current treatment strategies rely on the off-label use of medications for symptomatic treatment.

87 We also discuss off-label use of medications studied for obesity and pro

88 ar use of nonsedating antihistamines and the off-label use of omalizumab.

89 the design of future prospective trials for off-label use of oncology drugs across four areas: trial

90 For now, decisions about off-label use of recombinant factor VIIa remain at the p

91 From 2000 to 2008, off-label use of rFVIIa in hospitals increased more than

92 Off-label use of rFVIIa in the hospital setting far exce

93 anti-mammarenavirus therapy is limited to an off-label use of ribavirin that has limited efficacy.

94 rent antiarenaviral therapy is limited to an off-label use of ribavirin that is only partially effect

95 antiarenaviral therapy being limited to the off-label use of ribavirin that is only partially effect

96 rent antiarenaviral therapy is limited to an off-label use of ribavirin that is only partially effect

97 anti-mammarenaviral therapy is limited to an off-label use of ribavirin whose efficacy is controversi

98 ile antiarenaviral therapy is limited to the off-label use of ribavirin, which is only partially effe

99 and antiarenaviral therapy is limited to the off-label use of ribavirin, which is only partially effe

100 mammarenavirus infections is limited to the off-label use of ribavirin, which is partially effective

101 w-potency antipsychotics (eg, quetiapine) or off-label use of sedative antihistamines (eg, promethazi

102 To evaluate patterns and adverse outcomes of off-label use of TAVR in US clinical practice.

103 Off-label use of TAVR.

104 ion, nonrandomized clinical experiences with off-label use of tenecteplase vs alteplase for AIS treat

105 resources to perform a validation study for off-label use of the breakpoints on their systems.

106 ts (n = 20) with baricitinib according to an off-label use of the drug.

107 art failure code was evaluated for potential off-label use of the drug.

108 t therapeutic intervention is limited to the off-label use of the wide-spectrum antiviral ribavirin.

109 fferent outcomes were observed following the off-label use of the Woven EndoBridge, or WEB, device fo

110 tream infections potentially attributable to off-label use of these water heaters to warm extracorpor

111 The off-label use of tirofiban might have affected our resul

112 To better assess the safety and efficacy of off-label use of Tpo-RAs during pregnancy, a multicenter

113 sis of these preliminary findings, temporary off-label use of Tpo-RAs for severe and/or refractory IT

114 Off-label use of transcatheter aortic and pulmonary valv

115 rm prophylactic treatment relies on lithium, off-label use of valproate, and growing use of modern an

116 Off-label use of vemurafenib (VMF) to treat BRAF(V600E)

117 Off-label use of VPA and other HDAC inhibitors for the t

118 Small-scale reports have evaluated the off-label use of WEB devices for the treatment of sidewa

119 Trials were for off-label uses of gabapentin sponsored by Pfizer and Par

120 al companies have paid physicians to promote off-label uses of their products through a number of dif

121 Finally, "off-label" use of intravenous Ig has been evaluated for

122 rent antiarenaviral therapy is limited to an off-labeled use of the nucleoside analog ribavirin, whic

123 Prevalence of off-label use ranged from 3.5% for both drugs to 12.4% f

124 cally appropriate cancer therapies including off-label uses recognized by established drug compendia

125 Among 3046 patients with cancer, 695 off-label use reimbursement requests in 303 different in

126 th Food and Drug Administration-approved and off-label use, respectively.

127 N-supported off-label indication, and 10% of off-label use was associated with an FDA-approved cancer

128 Potential off-label use was defined as no recorded diagnosis of ei

129 Off-label use was defined as use among adults with a rec

130 Off-label use was defined as use in restenotic lesions,

131 All other use was "off-label." Off-label use was divided by whether it conformed to Nat

132 Off-label use was intended as first-line treatment in 31

133 rventions were excluded, however, risk after off-label use was not significantly increased (P=0.23).

134 physician, and hospital characteristics with off-label use were explored with multivariable hierarchi

135 ependently associated with increased odds of off-label use, whereas diabetes mellitus, increasing age

136 and Drug Administration approval and 18 with off-label use with subjective benefit).

137 Delays in evaluation may result in off-label use without dosing information as the only acc